Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Conference Call February 28, 2024 8:30 AM ET Company Participants Rachel Frank - Associate Director of Investor Relations Sanj Patel - Chief Executive Officer Ross Moat - Senior Vice President & Chief Commercial Officer John Paolini - Senior Vice President & Chief Medical Officer Mark Ragosa - Senior Vice President & Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Paul Choi - Goldman Sachs Operator Good day and thank you ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Incorporation or Organization) Identification No.) Kiniksa Pharmaceuticals, Ltd. Clarendon House 2 Church Street Hamilton HM11, Bermuda (808) 451-3453 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transiti ...

Financial Performance - ARCALYST net product revenue is expected to be $220-$230 million in 2023, representing approximately 84% growth at the midpoint[7, 25] - Q3 2023 ARCALYST net sales reached $64.8 million, a ~94% year-over-year growth compared to $33.4 million in Q3 2022[9, 32, 46] - The company's cash, cash equivalents, and short-term investments amounted to $201.1 million as of September 30, 2023[7, 31] - The company anticipates its cash reserves will fund the current operating plan into at least 2027[7, 47] ARCALYST Commercial Execution - ARCALYST has achieved >1,450 total prescribers[9] - Repeat prescribers account for approximately 24% of the total prescribers[9] - Payer approval rate for ARCALYST is >90% of completed cases[9] - Patient compliance with ARCALYST therapy is >85%[9] - Only 5% penetration of target recurrent pericarditis population as of YE22[7] KPL-404 Program - KPL-404 is currently in a Phase 2 study and is considered a potentially best-in-class asset[7]

Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Rachel Frank - Associate Director, IR Sanj Patel - CEO Ross Moat - SVP and CCO Mark Ragosa - SVP and CFO John Paolini - SVP and CMO Conference Call Participants Anupam Rama - JPMorgan Paul Choi - Goldman Sachs David Nierengarten - Wedbush Securities Liisa Bayko - Evercore ISI Operator Good day and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Third Quarter 2023 Earn ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR (Address, zip code and telephone number, including area code of principal executive offices) Kiniksa Pharmaceuticals Corp. 100 Hayden Avenue Lexington, MA, 02421 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the tr ...

Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) Q2 2023 Q2 2023 Earnings Call Transcript July 25, 2023 8:30 AM ET Company Participants Rachel Frank - Associate Director of Investor Relations Sanj Patel - Chief Executive Officer Ross Moat - Senior VP & Chief Commercial Officer Eben Tessari - Chief Operating Officer Mark Ragosa - Senior VP & CFO John Paolini - Senior VP & Chief Medical Officer Conference Call Participants Anupam Rama - JPMorgan Paul Choi - Goldman Sachs Alexandria Hammond - BofA David Nierengarten ...

14K multiple recurrence target patient population Time 2021 2022 2023 Based on first and only FDA-approved therapy for recurrent pericarditis, in-line with specialty biologics with Breakthrough Therapy and Orphan Drug designation • Payer engagement has increased awareness of recurrent pericarditis and the differentiated value of ARCALYST • The distribution network for ARCALYST was developed to provide a high and consistent level of patient support with broad access. Network pharmacies provide customized ser ...

| --- | --- | --- | --- | --- | |-------|-------|----------------------------|-------|-------| | | | | | | | | | First Quarter 2023 | | | | | | | | | | | | Financial Results and | | | | | | Recent Portfolio Execution | | | | --- | |--------------------------------------------------------------------------------| | | | Introduction \| Sanj K. Patel, Chief Executive Officer | | ARCALYST ® Commercial Execution \| Ross Moat, Chief Commercial Officer | | First Quarter 2023 Financial Results \| Mark Ragosa, Chief ...

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2023 Earnings Conference Call May 2, 2023 8:30 AM ET Company Participants Rachel Frank - Head of Investor Relations Sanj Patel - Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer John Paolini - Chief Medical Officer Conference Call Participants Paul Choi - Goldman Sachs Geoff Meacham - Bank of America Operator Good day and thank you for standing by and welcome to the Kiniksa Pharmaceuticals First Quarter 2023 Ear ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38492 Kiniksa Pharmaceuticals, Ltd. (Exact Name of Registrant as Specified in Its Charter) Bermuda 98-1327726 ...